metformin has been researched along with Fibrosis in 79 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The potential protective outcome of the antidiabetic and pleiotropic drug metformin against TAA-induced chronic kidney disease in association with the modulation of AMP-activated protein kinase (AMPK), oxidative stress, inflammation, dyslipidemia, and systemic hypertension has not been investigated before." | 8.31 | Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension. ( Al-Ani, B; Albawardi, A; Alqahtani, SM; Alshahrani, MY; Bayoumy, NM; Ebrahim, HA; Haidara, MA; Kamar, SS; ShamsEldeen, AM, 2023) |
| "These findings show that metformin provides substantial protection against diabetic cardiomyopathy-induced ROS-p53 mediated fibrosis and dyslipidemia." | 8.31 | Metformin ameliorates ROS-p53-collagen axis of fibrosis and dyslipidemia in type 2 diabetes mellitus-induced left ventricular injury. ( Al-Ani, B; Al-Hashem, F; Alzamil, NM; Bin-Jaliah, I; Dawood, AF; Haidara, MA; Hewett, PW; Kamar, SS; Latif, NSA; Shatoor, AS, 2023) |
| " Metformin, one of the most extensively used oral drugs against type 2 diabetes has recently been found to suppress tissue fibrosis as well." | 8.02 | Effect of metformin treatment and its time of administration on joint capsular fibrosis induced by mouse knee immobilization. ( Kawasaki, M; Mano, Y; Nakamura, E; Sakai, A; Suzuki, H; Tajima, T; Tokuda, K; Tsukamoto, M; Uchida, S; Wang, KY; Yamanaka, Y, 2021) |
| "This study demonstrates that metformin is able to attenuate HHcy-induced cardiac hypertrophy by decreasing myocardial fibrosis and apoptosis." | 8.02 | Metformin decreased myocardial fibrosis and apoptosis in hyperhomocysteinemia -induced cardiac hypertrophy. ( Huang, J; Song, W; Wang, D; Xu, C; Zhao, Q, 2021) |
| "This study aimed at comparing the effects of metformin on tubulointerstitial fibrosis (TIF) in different stages of diabetic nephropathy (DN) in vivo and evaluating the mechanism in high glucose (HG)-treated renal tubular epithelial cells (RTECs) in vitro." | 8.02 | Metformin attenuates renal tubulointerstitial fibrosis via upgrading autophagy in the early stage of diabetic nephropathy. ( Shi, K; Sun, D; Sun, H; Wang, F; Zhang, C; Zhang, X; Zuo, B, 2021) |
| "These data support a novel hypothesis that unifies the primary nonhereditary ovarian cancer risk factors through the development of ovarian fibrosis and the formation of a premetastatic niche, and suggests a potential use for metformin in ovarian cancer prophylaxis." | 7.96 | Metformin Abrogates Age-Associated Ovarian Fibrosis. ( Allen, CH; Azzi, F; Boyd, RW; Cook, DP; Forsyth, A; Gray, DA; Kelly, BS; Lo, B; McCloskey, CW; Murugkar, S; Rayner, KJ; Senterman, MK; Trudel, D; Upham, J; Vanderhyden, BC, 2020) |
| "Metformin with reduction of ECM component as collagen VI, MMP2 and MMP9, integrin/ERK pathway, necrosis markers as RIPK1, RIPK3 and MLKL, and apoptosis markers including DAP, DAPK1, DAPK3 and SIVA effects on fibrosis in insulin resistant and hypertrophied adipocytes in vitro." | 7.91 | Metformin reduces fibrosis factors in insulin resistant and hypertrophied adipocyte via integrin/ERK, collagen VI, apoptosis, and necrosis reduction. ( Malekpour-Dehkordi, Z; Mohiti-Ardakani, J; Naghiaee, Y; Nourbakhsh, M; Sharifi, R; Teimourian, S, 2019) |
| "In conclusion, our study revealed new therapeutic potential of metformin to attenuate calcineurin inhibitor-induced renal fibrosis, which was closely related to the suppression of MEK/ERK1/2 pathway." | 7.91 | Metformin Attenuates Cyclosporine A-induced Renal Fibrosis in Rats. ( Huang, YX; Li, Y; Liang, S; Lin, CX; Liu, SY; Su, YF; Tao, J; Zhang, LS; Zhao, ZK; Zheng, JM, 2019) |
| "Metformin is a well-known AMP-activated protein kinase (AMPK) activator, and it has been shown to inhibit organ fibrosis." | 7.85 | Metformin attenuates renal fibrosis in both AMPKα2-dependent and independent manners. ( Feng, Y; Wang, S; Xiao, H; Zhang, Y, 2017) |
| "The purpose of this study is to assess the potential effects of metformin on the development of EMT and tubulointerstitial fibrosis 12 weeks after acute renal ischemia-reperfusion." | 7.83 | Metformin alleviated EMT and fibrosis after renal ischemia-reperfusion injury in rats. ( Chen, Z; Guo, J; Jiang, G; Liu, X; Wang, M; Weng, X, 2016) |
| "Oral administration of metformin or resveratrol prevented hypoxia and reduced HIF-1α accumulation with dephosphorylation of inositol-requiring enzyme 1α and eukaryotic initiation factor 2α, indicative of suppression of hypoxic HIF-1α activation and endoplasmic reticulum stress." | 7.83 | The role of metformin and resveratrol in the prevention of hypoxia-inducible factor 1α accumulation and fibrosis in hypoxic adipose tissue. ( Huang, F; Kou, J; Li, A; Li, J; Li, X; Liu, B; Liu, K; Qi, LW; Qiu, Z; Wang, L, 2016) |
| " Earlier studies from our group have revealed that clinically-relevant concentrations of the biguanide derivative metformin, the most widely used oral agent to lower blood glucose concentration in patients with type 2 diabetes and metabolic syndrome, notably decreased both the self-renewal and the proliferation of trastuzumab-refractory breast cancer stem cell populations." | 7.76 | Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. ( Cufí, S; Joven, J; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2010) |
| "Metformin inhibited cardiac fibrosis induced by pressure overload in vivo and inhibited collagen synthesis in CFs probably via inhibition of the TGF-beta(1)-Smad3 signalling pathway." | 7.76 | Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. ( Feng, W; Fu, Y; Lu, Z; Ma, X; Shen, Q; Xiao, H; Xu, M; Zhang, Y; Zhu, Y, 2010) |
| "Metformin attenuated oxidative stress-induced cardiomyocyte apoptosis and prevented the progression of heart failure in dogs, along with activation of AMPK." | 7.75 | Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. ( Asakura, M; Asanuma, H; Fujita, M; Ito, S; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Mochizuki, N; Ogai, A; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2009) |
| "Liver fibrosis is a disease with significant morbidity and mortality." | 7.01 | Research progress of metformin in the treatment of liver fibrosis. ( Hu, C; Huang, Y; Li, B; Li, Y; Qian, F; Sun, W; Yang, F; Zhang, A, 2023) |
| "Glaucoma is the leading cause of irreversible blindness globally." | 6.72 | Metformin and Glaucoma-Review of Anti-Fibrotic Processes and Bioenergetics. ( Hurley, DJ; Irnaten, M; O'Brien, C, 2021) |
| "Metformin, which is a potent AMPK activator and is the only recommended first-line drug for the treatment of type 2 diabetes, has emerged as a promising method of fibrosis reduction or reversion." | 6.72 | Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms. ( Guo, M; Liu, J; Long, Y; Tan, X; Wan, S; Wu, M; Xu, H; Xu, Y, 2021) |
| "Metformin, a type 2 diabetes mellitus (T2DM) medication, has been noted for its potent anti-fibrotic effects." | 5.91 | Metformin Attenuates TGF-β1-Induced Fibrosis in Salivary Gland: A Preliminary Study. ( Chen, Z; Cheng, Y; Li, B; Li, Y; Peng, B; Wang, L; Wang, X; Wei, L; Zhong, NN, 2023) |
| "As metformin has multiple therapeutic effects in many autoimmune diseases, we explored the effects of metformin on TAO in an in vitro fibroblast model." | 5.72 | Metformin Attenuates Inflammation and Fibrosis in Thyroid-Associated Ophthalmopathy. ( Sha, X; Sun, A; Xiao, W; Xu, Z; Yang, H; Yang, S; Ye, H; Zhang, T, 2022) |
| "Tofacitinib is a pan-JAK inhibitör." | 5.72 | Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis. ( Akar, ZA; Akkoc, RF; Celik, C; Dagli, AF; Etem, EO; Karatas, A; Koca, SS; Oz, B, 2022) |
| "Metformin is a well-known pharmacological agent for the treatment of diabetes; however, the application of large doses of the drug is limited by its side effects." | 5.72 | Co-administration of hydrogen and metformin exerts cardioprotective effects by inhibiting pyroptosis and fibrosis in diabetic cardiomyopathy. ( Bai, J; Hong, X; Liu, J; Nie, C; Pan, S; Wang, B; Xi, S; Yang, W; Yu, M; Zou, R, 2022) |
| "Suppression of inflammation is an effective therapeutic strategy for treating cardiac fibrosis and HF." | 5.72 | Gentiopicroside alleviates cardiac inflammation and fibrosis in T2DM rats through targeting Smad3 phosphorylation. ( Hu, XP; Huang, P; Huang, ZJ; Liu, T; Pan, ZF; Shi, JN; Sun, ZY; Xu, YN; Yuan, MN; Zhang, YW; Zou, XZ, 2022) |
| "Ovarian fibrosis is a pathological condition associated with aging and is responsible for a variety of ovarian dysfunctions." | 5.72 | Metformin prevents age-associated ovarian fibrosis by modulating the immune landscape in female mice. ( Cook, DP; Fasih, S; Landry, DA; Upham, J; Vanderhyden, BC; Yakubovich, E, 2022) |
| "Metformin treatment markedly reduced postinfarction fibrotic remodeling and CD68-positive cell population in mice." | 5.62 | Metformin Attenuates Postinfarction Myocardial Fibrosis and Inflammation in Mice. ( Boal, F; Cussac, D; Korda, M; Kramar, S; Kunduzova, O; Laborde, C; Loi, H; Marsal, D; Oleshchuk, O; Pizzinat, N; Roncalli, J; Tronchere, H, 2021) |
| "Although the pathogenesis of systemic sclerosis is not exactly known, it is thought that immune activation has prominent roles in pathogenesis." | 5.62 | Secukinumab and metformin ameliorate dermal fibrosis by decreasing tissue interleukin-17 levels in bleomycin-induced dermal fibrosis. ( Akar, ZA; Celik, C; Dagli, AF; Etem, EO; Karatas, A; Koca, SS; Oz, B, 2021) |
| " In the present study, we took advantage of a transgenic mouse (TG221) characterized by microRNA-221 overexpression, with cirrhotic liver background induced by chronic administration of carbon tetrachloride (CCl4)." | 5.51 | Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. ( Callegari, E; Gramantieri, L; Guerriero, P; Negrini, M; Pinton, P; Rimessi, A; Sabbioni, S; Shankaraiah, RC; Silini, EM, 2019) |
| "Metformin has been the most prescribed glucose-lowering medicine worldwide, and its potential for many other therapeutic applications is also being explored intensively." | 5.48 | Metformin attenuates folic-acid induced renal fibrosis in mice. ( Cao, Q; Chen, J; Chen, XM; Huang, C; Pollock, CA; Shi, Y; Yi, H; Zhang, L; Zhao, Y, 2018) |
| "Skin fibrosis was analyzed by staining with H&E and Masson's trichrome stain." | 5.48 | Metformin Alleviates Radiation-Induced Skin Fibrosis via the Downregulation of FOXO3. ( Byeon, HJ; Cho, J; Choi, WH; Han, SY; Kang, JW; Kim, CS; Kim, JM; Kim, JY; Lee, EJ; Lee, WJ; Lee, YS; Oh, SH; Yoo, BR; Yoo, H, 2018) |
| " The main risk factors for developing HCC are well known and include hepatitis B and C virus infection, alcohol intake and ingestion of the fungal metabolite aflatoxin B1." | 4.93 | Hepatocellular carcinoma. ( Gores, G; Llovet, JM; Pikarsky, E; Sangro, B; Schwartz, M; Sherman, M; Zucman-Rossi, J, 2016) |
| " We will discuss a range of adverse events to iodinated and gadolinium-based contrast agents, including allergic-like reactions, nephrotoxicity, extravasation, and nephrogenic systemic fibrosis." | 4.91 | Intravenous Imaging Contrast Media Complications: The Basics That Every Clinician Needs to Know. ( Choi, JW; Rose, TA, 2015) |
| " The potential protective outcome of the antidiabetic and pleiotropic drug metformin against TAA-induced chronic kidney disease in association with the modulation of AMP-activated protein kinase (AMPK), oxidative stress, inflammation, dyslipidemia, and systemic hypertension has not been investigated before." | 4.31 | Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension. ( Al-Ani, B; Albawardi, A; Alqahtani, SM; Alshahrani, MY; Bayoumy, NM; Ebrahim, HA; Haidara, MA; Kamar, SS; ShamsEldeen, AM, 2023) |
| " We tested the drugs metformin (AMPK activator) and baicalin (CPT1A activator) in different experimental models mimicking COVID-19 associated inflammation in lung and kidney." | 4.31 | Enhanced fatty acid oxidation through metformin and baicalin as therapy for COVID-19 and associated inflammatory states in lung and kidney. ( Alcalde-Estévez, E; Castillo, C; Castro, A; Costa, IG; Fernández, L; Herrero, JI; Jansen, J; Kramann, R; Lamas, S; Miguel, V; Nagai, J; Ranz, I; Reimer, KC; Rey-Serra, C; Rodríguez González-Moro, JM; Sancho, D; Sevilla, L; Sirera, B; Tituaña, J, 2023) |
| "These findings show that metformin provides substantial protection against diabetic cardiomyopathy-induced ROS-p53 mediated fibrosis and dyslipidemia." | 4.31 | Metformin ameliorates ROS-p53-collagen axis of fibrosis and dyslipidemia in type 2 diabetes mellitus-induced left ventricular injury. ( Al-Ani, B; Al-Hashem, F; Alzamil, NM; Bin-Jaliah, I; Dawood, AF; Haidara, MA; Hewett, PW; Kamar, SS; Latif, NSA; Shatoor, AS, 2023) |
| "5 % cholic acid and 60 % cocoa butter for 6 weeks causing a number of metabolic and hepatic alterations including insulin resistance, dyslipidemia, systemic inflammation, increased hepatic oxidative stress and lipid peroxidation, hepatic steatosis, lobular inflammation, as well as increased markers of liver inflammation and hepatocyte apoptosis." | 4.12 | Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms. ( Aly, RG; Alzaim, I; El-Mallah, A; El-Yazbi, AF; Shaaban, HH; Wahid, A, 2022) |
| "This study aimed at comparing the effects of metformin on tubulointerstitial fibrosis (TIF) in different stages of diabetic nephropathy (DN) in vivo and evaluating the mechanism in high glucose (HG)-treated renal tubular epithelial cells (RTECs) in vitro." | 4.02 | Metformin attenuates renal tubulointerstitial fibrosis via upgrading autophagy in the early stage of diabetic nephropathy. ( Shi, K; Sun, D; Sun, H; Wang, F; Zhang, C; Zhang, X; Zuo, B, 2021) |
| " Metformin, one of the most extensively used oral drugs against type 2 diabetes has recently been found to suppress tissue fibrosis as well." | 4.02 | Effect of metformin treatment and its time of administration on joint capsular fibrosis induced by mouse knee immobilization. ( Kawasaki, M; Mano, Y; Nakamura, E; Sakai, A; Suzuki, H; Tajima, T; Tokuda, K; Tsukamoto, M; Uchida, S; Wang, KY; Yamanaka, Y, 2021) |
| "This study demonstrates that metformin is able to attenuate HHcy-induced cardiac hypertrophy by decreasing myocardial fibrosis and apoptosis." | 4.02 | Metformin decreased myocardial fibrosis and apoptosis in hyperhomocysteinemia -induced cardiac hypertrophy. ( Huang, J; Song, W; Wang, D; Xu, C; Zhao, Q, 2021) |
| "These data support a novel hypothesis that unifies the primary nonhereditary ovarian cancer risk factors through the development of ovarian fibrosis and the formation of a premetastatic niche, and suggests a potential use for metformin in ovarian cancer prophylaxis." | 3.96 | Metformin Abrogates Age-Associated Ovarian Fibrosis. ( Allen, CH; Azzi, F; Boyd, RW; Cook, DP; Forsyth, A; Gray, DA; Kelly, BS; Lo, B; McCloskey, CW; Murugkar, S; Rayner, KJ; Senterman, MK; Trudel, D; Upham, J; Vanderhyden, BC, 2020) |
| "Metformin, an AMP-activated protein kinase (AMPK) activator, has been shown in previous studies to reduce kidney fibrosis in different models of experimental chronic kidney disease (CKD)." | 3.96 | Metformin arrests the progression of established kidney disease in the subtotal nephrectomy model of chronic kidney disease. ( Borges, CM; de Ávila, VF; Formigari, GP; Fujihara, CK; Lopes de Faria, JB; Malheiros, DMAC, 2020) |
| "Metformin with reduction of ECM component as collagen VI, MMP2 and MMP9, integrin/ERK pathway, necrosis markers as RIPK1, RIPK3 and MLKL, and apoptosis markers including DAP, DAPK1, DAPK3 and SIVA effects on fibrosis in insulin resistant and hypertrophied adipocytes in vitro." | 3.91 | Metformin reduces fibrosis factors in insulin resistant and hypertrophied adipocyte via integrin/ERK, collagen VI, apoptosis, and necrosis reduction. ( Malekpour-Dehkordi, Z; Mohiti-Ardakani, J; Naghiaee, Y; Nourbakhsh, M; Sharifi, R; Teimourian, S, 2019) |
| "In conclusion, our study revealed new therapeutic potential of metformin to attenuate calcineurin inhibitor-induced renal fibrosis, which was closely related to the suppression of MEK/ERK1/2 pathway." | 3.91 | Metformin Attenuates Cyclosporine A-induced Renal Fibrosis in Rats. ( Huang, YX; Li, Y; Liang, S; Lin, CX; Liu, SY; Su, YF; Tao, J; Zhang, LS; Zhao, ZK; Zheng, JM, 2019) |
| "Metformin is a well-known AMP-activated protein kinase (AMPK) activator, and it has been shown to inhibit organ fibrosis." | 3.85 | Metformin attenuates renal fibrosis in both AMPKα2-dependent and independent manners. ( Feng, Y; Wang, S; Xiao, H; Zhang, Y, 2017) |
| "Oral administration of metformin or resveratrol prevented hypoxia and reduced HIF-1α accumulation with dephosphorylation of inositol-requiring enzyme 1α and eukaryotic initiation factor 2α, indicative of suppression of hypoxic HIF-1α activation and endoplasmic reticulum stress." | 3.83 | The role of metformin and resveratrol in the prevention of hypoxia-inducible factor 1α accumulation and fibrosis in hypoxic adipose tissue. ( Huang, F; Kou, J; Li, A; Li, J; Li, X; Liu, B; Liu, K; Qi, LW; Qiu, Z; Wang, L, 2016) |
| "The purpose of this study is to assess the potential effects of metformin on the development of EMT and tubulointerstitial fibrosis 12 weeks after acute renal ischemia-reperfusion." | 3.83 | Metformin alleviated EMT and fibrosis after renal ischemia-reperfusion injury in rats. ( Chen, Z; Guo, J; Jiang, G; Liu, X; Wang, M; Weng, X, 2016) |
| " What is the main finding and its importance? We demonstrated, for the first time, that DPP-4 inhibitor, but not metformin, exerted similar efficacy in improving cardiac function and attenuating cardiac fibrosis compared with enalapril in rats with chronic MI." | 3.81 | Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction. ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Inthachai, T; Kumfu, S; Lekawanvijit, S; Pongkan, W, 2015) |
| " Earlier studies from our group have revealed that clinically-relevant concentrations of the biguanide derivative metformin, the most widely used oral agent to lower blood glucose concentration in patients with type 2 diabetes and metabolic syndrome, notably decreased both the self-renewal and the proliferation of trastuzumab-refractory breast cancer stem cell populations." | 3.76 | Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. ( Cufí, S; Joven, J; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2010) |
| "Metformin inhibited cardiac fibrosis induced by pressure overload in vivo and inhibited collagen synthesis in CFs probably via inhibition of the TGF-beta(1)-Smad3 signalling pathway." | 3.76 | Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. ( Feng, W; Fu, Y; Lu, Z; Ma, X; Shen, Q; Xiao, H; Xu, M; Zhang, Y; Zhu, Y, 2010) |
| "Metformin attenuated oxidative stress-induced cardiomyocyte apoptosis and prevented the progression of heart failure in dogs, along with activation of AMPK." | 3.75 | Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. ( Asakura, M; Asanuma, H; Fujita, M; Ito, S; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Mochizuki, N; Ogai, A; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2009) |
| "Liver fibrosis is a disease with significant morbidity and mortality." | 3.01 | Research progress of metformin in the treatment of liver fibrosis. ( Hu, C; Huang, Y; Li, B; Li, Y; Qian, F; Sun, W; Yang, F; Zhang, A, 2023) |
| "Metformin, which is a potent AMPK activator and is the only recommended first-line drug for the treatment of type 2 diabetes, has emerged as a promising method of fibrosis reduction or reversion." | 2.72 | Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms. ( Guo, M; Liu, J; Long, Y; Tan, X; Wan, S; Wu, M; Xu, H; Xu, Y, 2021) |
| "Glaucoma is the leading cause of irreversible blindness globally." | 2.72 | Metformin and Glaucoma-Review of Anti-Fibrotic Processes and Bioenergetics. ( Hurley, DJ; Irnaten, M; O'Brien, C, 2021) |
| "Fibrosis is a general term encompassing a plethora of pathologies that span all systems and is marked by increased deposition of collagen." | 2.53 | AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation. ( Beauloye, C; Bertrand, L; Daskalopoulos, EP; Dufeys, C; Horman, S, 2016) |
| "Obesity is known to be the most common cause of simple steatosis in the preadolescent and adolescent population with a consequent serious health risk." | 2.47 | [Fatty liver and its clinical management in obese adolescents]. ( Álvarez Ferre, J; González Jiménez, E; Schmidt Río-Valle, J, 2011) |
| "Metformin, a type 2 diabetes mellitus (T2DM) medication, has been noted for its potent anti-fibrotic effects." | 1.91 | Metformin Attenuates TGF-β1-Induced Fibrosis in Salivary Gland: A Preliminary Study. ( Chen, Z; Cheng, Y; Li, B; Li, Y; Peng, B; Wang, L; Wang, X; Wei, L; Zhong, NN, 2023) |
| "Cardiac fibrosis was analyzed using immunohistochemistry, Masson's trichrome staining, and Western blot analysis." | 1.91 | Metformin suppresses cardiac fibroblast proliferation under high-glucose conditions via regulating the mitochondrial complex I protein Grim-19 involved in the Sirt1/Stat3 signaling pathway. ( Cui, X; Han, B; Li, Y; Liu, X; Ma, S; Pan, H; Wan, L; Wei, J, 2023) |
| "Metformin was administered via drinking water to mice with a unilateral ureteric obstruction (UUO) model of renal fibrosis." | 1.91 | Mutation of regulatory phosphorylation sites in PFKFB2 does not affect the anti-fibrotic effect of metformin in the kidney. ( Gleich, K; Harley, G; Katerelos, M; Lee, M; Mount, PF; Power, DA, 2023) |
| "Ascites is associated with a high risk of death." | 1.72 | Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans. ( Mazumder, N; Parikh, ND; Tapper, EB; Zhao, Z, 2022) |
| "Tofacitinib is a pan-JAK inhibitör." | 1.72 | Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis. ( Akar, ZA; Akkoc, RF; Celik, C; Dagli, AF; Etem, EO; Karatas, A; Koca, SS; Oz, B, 2022) |
| "As metformin has multiple therapeutic effects in many autoimmune diseases, we explored the effects of metformin on TAO in an in vitro fibroblast model." | 1.72 | Metformin Attenuates Inflammation and Fibrosis in Thyroid-Associated Ophthalmopathy. ( Sha, X; Sun, A; Xiao, W; Xu, Z; Yang, H; Yang, S; Ye, H; Zhang, T, 2022) |
| "Ovarian fibrosis is a pathological condition associated with aging and is responsible for a variety of ovarian dysfunctions." | 1.72 | Metformin prevents age-associated ovarian fibrosis by modulating the immune landscape in female mice. ( Cook, DP; Fasih, S; Landry, DA; Upham, J; Vanderhyden, BC; Yakubovich, E, 2022) |
| "Suppression of inflammation is an effective therapeutic strategy for treating cardiac fibrosis and HF." | 1.72 | Gentiopicroside alleviates cardiac inflammation and fibrosis in T2DM rats through targeting Smad3 phosphorylation. ( Hu, XP; Huang, P; Huang, ZJ; Liu, T; Pan, ZF; Shi, JN; Sun, ZY; Xu, YN; Yuan, MN; Zhang, YW; Zou, XZ, 2022) |
| "Metformin is a well-known pharmacological agent for the treatment of diabetes; however, the application of large doses of the drug is limited by its side effects." | 1.72 | Co-administration of hydrogen and metformin exerts cardioprotective effects by inhibiting pyroptosis and fibrosis in diabetic cardiomyopathy. ( Bai, J; Hong, X; Liu, J; Nie, C; Pan, S; Wang, B; Xi, S; Yang, W; Yu, M; Zou, R, 2022) |
| "Metformin was administered in the drinking water (200 mg/kg/d) for 24 weeks." | 1.62 | AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice. ( Han, YC; Li, AM; Liu, YT; Peng, CH; Song, N; Tang, SQ; Wu, XQ; Yang, M; Yang, S; Zhan, M; Zhang, H; Zhang, W, 2021) |
| "Although the pathogenesis of systemic sclerosis is not exactly known, it is thought that immune activation has prominent roles in pathogenesis." | 1.62 | Secukinumab and metformin ameliorate dermal fibrosis by decreasing tissue interleukin-17 levels in bleomycin-induced dermal fibrosis. ( Akar, ZA; Celik, C; Dagli, AF; Etem, EO; Karatas, A; Koca, SS; Oz, B, 2021) |
| " This study aimed to evaluate the role of Met as anti-schistosomal and anti-fibrotic agents alone or in combination with PZQ treatment." | 1.62 | An adjuvant effect of Metformin as an anti-fibrotic agent when administered with the anti-schistosomal Praziquantel in Schistosoma mansoni infected mice. ( El-Naggar, SA; El-Said, KS; Harras, SF; Salama, WM, 2021) |
| "Treatment with metformin suppressed the activation of Smad3 and compensated the diminished autophagy in 9-wk pBOO rat bladders." | 1.62 | Metformin ameliorates bladder dysfunction in a rat model of partial bladder outlet obstruction. ( Chen, L; Cui, J; Gao, Z; Jiang, X; Li, Y; Liu, Y; Lv, L; Shi, B; Wang, S; Xia, Y; Zhang, L; Zhang, X; Zhou, N, 2021) |
| "Metformin treatment markedly reduced postinfarction fibrotic remodeling and CD68-positive cell population in mice." | 1.62 | Metformin Attenuates Postinfarction Myocardial Fibrosis and Inflammation in Mice. ( Boal, F; Cussac, D; Korda, M; Kramar, S; Kunduzova, O; Laborde, C; Loi, H; Marsal, D; Oleshchuk, O; Pizzinat, N; Roncalli, J; Tronchere, H, 2021) |
| "Metformin is an AMP kinase (AMPK) activator, the widest used antidiabetic drug." | 1.62 | Metformin impairs homing ability and efficacy of mesenchymal stem cells for cardiac repair in streptozotocin-induced diabetic cardiomyopathy in rats. ( Ammar, HI; Ashour, H; Dhingra, S; Fadel, M; Kamar, SS; Rashed, LA; Shamseldeen, AM; Shoukry, HS; Srivastava, A, 2021) |
| "Fibrosis was significantly less in treated mice atria." | 1.62 | Activation of AMP-Activated Protein Kinases Prevents Atrial Fibrillation. ( Dixit, G; Li, Z; Ozcan, C, 2021) |
| " In the present study, we took advantage of a transgenic mouse (TG221) characterized by microRNA-221 overexpression, with cirrhotic liver background induced by chronic administration of carbon tetrachloride (CCl4)." | 1.51 | Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. ( Callegari, E; Gramantieri, L; Guerriero, P; Negrini, M; Pinton, P; Rimessi, A; Sabbioni, S; Shankaraiah, RC; Silini, EM, 2019) |
| "Metformin is a biguanide derivative widely used for the treatment of type 2 diabetes mellitus." | 1.51 | Metformin inhibits TGF-beta 1-induced MCP-1 expression through BAMBI-mediated suppression of MEK/ERK1/2 signalling. ( Li, Y; Liang, D; Liang, W; Liu, S; Song, Z, 2019) |
| "Metformin (MET) has anti-inflammatory and anti-fibrotic effects, but its effect on the in vivo pathogenesis of scleroderma remains unknown." | 1.51 | Metformin attenuates bleomycin-induced scleroderma by regulating the balance of Treg/Teff cells and reducing spleen germinal center formation. ( Feng, M; Gao, C; Guo, H; Li, X; Liang, Z; Luo, J; Qin, K; Wang, Y; Zhang, S; Zhao, X, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) may be associated with changes in bile acid (BA) metabolism." | 1.51 | Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. ( Appleby, RN; Khan, S; Manousou, P; Moghul, I; Neal, TD; Walters, JRF; Yee, M, 2019) |
| "Metformin was injected intraperitoneally after surgery." | 1.51 | Metformin Promotes Regeneration of the Injured Endometrium Via Inhibition of Endoplasmic Reticulum Stress-Induced Apoptosis. ( Ansong, E; Lin, HL; Lin, Q; Shen, LE; Wu, XQ; Xu, XX; Zhang, SS, 2019) |
| "Skin fibrosis was analyzed by staining with H&E and Masson's trichrome stain." | 1.48 | Metformin Alleviates Radiation-Induced Skin Fibrosis via the Downregulation of FOXO3. ( Byeon, HJ; Cho, J; Choi, WH; Han, SY; Kang, JW; Kim, CS; Kim, JM; Kim, JY; Lee, EJ; Lee, WJ; Lee, YS; Oh, SH; Yoo, BR; Yoo, H, 2018) |
| "Metformin has been the most prescribed glucose-lowering medicine worldwide, and its potential for many other therapeutic applications is also being explored intensively." | 1.48 | Metformin attenuates folic-acid induced renal fibrosis in mice. ( Cao, Q; Chen, J; Chen, XM; Huang, C; Pollock, CA; Shi, Y; Yi, H; Zhang, L; Zhao, Y, 2018) |
| "This study suggests that atherosclerotic plaques in subjects with DM II are more prone to rupture because of impaired repair responses rather than to increased vascular inflammation." | 1.40 | Impaired fibrous repair: a possible contributor to atherosclerotic plaque vulnerability in patients with type II diabetes. ( Bengtsson, E; Björkbacka, H; Dunér, P; Edsfeldt, A; Gonçalves, I; Grufman, H; Melander, O; Mollet, IG; Nilsson, J; Nilsson, M; Nitulescu, M; Orho-Melander, M; Persson, A, 2014) |
| "Myocardial fibrosis is a key process in diabetic cardiomyopathy." | 1.39 | Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. ( Ares-Carrasco, S; Caro-Vadillo, A; Egido, J; Iborra, C; Lorenzo, O; Picatoste, B; Ramírez, E; Tuñón, J, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.27) | 29.6817 |
| 2010's | 36 (45.57) | 24.3611 |
| 2020's | 42 (53.16) | 2.80 |
| Authors | Studies |
|---|---|
| Loi, H | 1 |
| Kramar, S | 1 |
| Laborde, C | 1 |
| Marsal, D | 1 |
| Pizzinat, N | 1 |
| Cussac, D | 1 |
| Roncalli, J | 1 |
| Boal, F | 1 |
| Tronchere, H | 1 |
| Oleshchuk, O | 1 |
| Korda, M | 1 |
| Kunduzova, O | 1 |
| Tokuda, K | 1 |
| Yamanaka, Y | 1 |
| Mano, Y | 1 |
| Tsukamoto, M | 1 |
| Tajima, T | 1 |
| Suzuki, H | 1 |
| Kawasaki, M | 1 |
| Uchida, S | 1 |
| Nakamura, E | 1 |
| Wang, KY | 1 |
| Sakai, A | 1 |
| Hua, Z | 1 |
| Wei, P | 1 |
| Han, YC | 1 |
| Tang, SQ | 1 |
| Liu, YT | 1 |
| Li, AM | 1 |
| Zhan, M | 1 |
| Yang, M | 1 |
| Song, N | 1 |
| Zhang, W | 1 |
| Wu, XQ | 2 |
| Peng, CH | 1 |
| Zhang, H | 1 |
| Yang, S | 2 |
| Dong, X | 1 |
| Jin, X | 1 |
| Karatas, A | 2 |
| Oz, B | 2 |
| Celik, C | 2 |
| Akar, ZA | 2 |
| Akkoc, RF | 1 |
| Etem, EO | 2 |
| Dagli, AF | 2 |
| Koca, SS | 2 |
| Tapper, EB | 1 |
| Zhao, Z | 1 |
| Mazumder, N | 1 |
| Parikh, ND | 1 |
| Zou, R | 1 |
| Nie, C | 1 |
| Pan, S | 1 |
| Wang, B | 1 |
| Hong, X | 1 |
| Xi, S | 1 |
| Bai, J | 1 |
| Yu, M | 1 |
| Liu, J | 5 |
| Yang, W | 1 |
| Baeri, A | 1 |
| Levraut, M | 1 |
| Diazzi, S | 1 |
| Camuzard, O | 1 |
| Cegarra-Escolano, M | 1 |
| Ploumellec, MA | 1 |
| Balaguer, T | 1 |
| Fassy, J | 1 |
| Rezzonico, R | 1 |
| Bellusci, S | 1 |
| Mari, B | 1 |
| Vassaux, G | 1 |
| Zheng, D | 1 |
| Chen, L | 2 |
| Wei, Q | 1 |
| Zhu, Z | 1 |
| Liu, Z | 2 |
| Jin, L | 1 |
| Yang, G | 1 |
| Xie, X | 1 |
| Sun, H | 2 |
| Shi, K | 2 |
| Zuo, B | 2 |
| Zhang, X | 4 |
| Liu, Y | 4 |
| Sun, D | 2 |
| Wang, F | 3 |
| Zou, XZ | 1 |
| Zhang, YW | 1 |
| Pan, ZF | 1 |
| Hu, XP | 1 |
| Xu, YN | 1 |
| Huang, ZJ | 1 |
| Sun, ZY | 1 |
| Yuan, MN | 1 |
| Shi, JN | 1 |
| Huang, P | 1 |
| Liu, T | 1 |
| Landry, DA | 1 |
| Yakubovich, E | 1 |
| Cook, DP | 2 |
| Fasih, S | 1 |
| Upham, J | 2 |
| Vanderhyden, BC | 2 |
| Mahmoud, MF | 1 |
| Elmaghraby, AM | 1 |
| Ali, N | 1 |
| Mostafa, I | 1 |
| El-Shazly, AM | 1 |
| Abdelfattah, MAO | 1 |
| Sobeh, M | 1 |
| Shaaban, HH | 1 |
| Alzaim, I | 1 |
| El-Mallah, A | 1 |
| Aly, RG | 1 |
| El-Yazbi, AF | 1 |
| Wahid, A | 1 |
| Lu, J | 2 |
| Zhang, L | 4 |
| Zhang, Y | 4 |
| Gao, Y | 2 |
| Yuan, X | 2 |
| Xiang, M | 2 |
| Tang, Q | 2 |
| Septembre-Malaterre, A | 1 |
| Boina, C | 1 |
| Douanier, A | 1 |
| Gasque, P | 1 |
| Xu, Z | 1 |
| Ye, H | 1 |
| Xiao, W | 1 |
| Sun, A | 1 |
| Zhang, T | 1 |
| Sha, X | 1 |
| Yang, H | 1 |
| Zhang, A | 1 |
| Qian, F | 1 |
| Li, Y | 6 |
| Li, B | 2 |
| Yang, F | 1 |
| Hu, C | 1 |
| Sun, W | 1 |
| Huang, Y | 1 |
| Harley, G | 1 |
| Katerelos, M | 1 |
| Gleich, K | 1 |
| Lee, M | 1 |
| Mount, PF | 1 |
| Power, DA | 1 |
| Alshahrani, MY | 1 |
| Ebrahim, HA | 1 |
| Alqahtani, SM | 1 |
| Bayoumy, NM | 1 |
| Kamar, SS | 3 |
| ShamsEldeen, AM | 2 |
| Haidara, MA | 2 |
| Al-Ani, B | 2 |
| Albawardi, A | 1 |
| Li, D | 1 |
| Zhao, A | 1 |
| Zhu, J | 1 |
| Wang, C | 1 |
| Shen, J | 1 |
| Zheng, Z | 1 |
| Pan, F | 1 |
| Chen, Q | 2 |
| Yang, Y | 1 |
| Liu, X | 2 |
| Wan, L | 1 |
| Han, B | 1 |
| Ma, S | 1 |
| Pan, H | 1 |
| Wei, J | 1 |
| Cui, X | 1 |
| Petrocelli, JJ | 2 |
| McKenzie, AI | 2 |
| de Hart, NMMP | 1 |
| Reidy, PT | 2 |
| Mahmassani, ZS | 2 |
| Keeble, AR | 1 |
| Kaput, KL | 1 |
| Wahl, MP | 1 |
| Rondina, MT | 1 |
| Marcus, RL | 1 |
| Welt, CK | 1 |
| Holland, WL | 1 |
| Funai, K | 2 |
| Fry, CS | 1 |
| Drummond, MJ | 2 |
| Miguel, V | 1 |
| Rey-Serra, C | 1 |
| Tituaña, J | 1 |
| Sirera, B | 1 |
| Alcalde-Estévez, E | 1 |
| Herrero, JI | 1 |
| Ranz, I | 1 |
| Fernández, L | 1 |
| Castillo, C | 1 |
| Sevilla, L | 1 |
| Nagai, J | 1 |
| Reimer, KC | 1 |
| Jansen, J | 1 |
| Kramann, R | 1 |
| Costa, IG | 1 |
| Castro, A | 1 |
| Sancho, D | 1 |
| Rodríguez González-Moro, JM | 1 |
| Lamas, S | 1 |
| Wang, L | 2 |
| Zhong, NN | 1 |
| Wang, X | 1 |
| Peng, B | 1 |
| Chen, Z | 2 |
| Wei, L | 1 |
| Cheng, Y | 1 |
| Shankaraiah, RC | 1 |
| Callegari, E | 1 |
| Guerriero, P | 1 |
| Rimessi, A | 1 |
| Pinton, P | 1 |
| Gramantieri, L | 1 |
| Silini, EM | 1 |
| Sabbioni, S | 1 |
| Negrini, M | 1 |
| McCloskey, CW | 1 |
| Kelly, BS | 1 |
| Azzi, F | 1 |
| Allen, CH | 1 |
| Forsyth, A | 1 |
| Rayner, KJ | 1 |
| Gray, DA | 1 |
| Boyd, RW | 1 |
| Murugkar, S | 1 |
| Lo, B | 1 |
| Trudel, D | 1 |
| Senterman, MK | 1 |
| Gao, J | 1 |
| Yuan, J | 1 |
| Wang, Q | 1 |
| Lei, T | 1 |
| Shen, X | 1 |
| Cui, B | 1 |
| Zhang, F | 1 |
| Ding, W | 1 |
| Lu, Z | 2 |
| Borges, CM | 1 |
| Fujihara, CK | 1 |
| Malheiros, DMAC | 1 |
| de Ávila, VF | 1 |
| Formigari, GP | 1 |
| Lopes de Faria, JB | 1 |
| Ozcan, C | 1 |
| Dixit, G | 1 |
| Li, Z | 1 |
| Jeon, HB | 1 |
| Roh, H | 1 |
| Ahn, HM | 1 |
| Lee, JH | 1 |
| Yun, CO | 1 |
| Roh, TS | 1 |
| Lee, WJ | 2 |
| Zhao, Q | 1 |
| Song, W | 1 |
| Huang, J | 1 |
| Wang, D | 1 |
| Xu, C | 1 |
| Alzamil, NM | 1 |
| Hewett, PW | 1 |
| Al-Hashem, F | 1 |
| Bin-Jaliah, I | 1 |
| Shatoor, AS | 1 |
| Latif, NSA | 1 |
| Dawood, AF | 1 |
| Ammar, HI | 1 |
| Shoukry, HS | 1 |
| Ashour, H | 1 |
| Rashed, LA | 1 |
| Fadel, M | 1 |
| Srivastava, A | 1 |
| Dhingra, S | 1 |
| Song, Z | 2 |
| Wu, T | 1 |
| Sun, J | 1 |
| Wang, H | 1 |
| Hua, F | 1 |
| Nicolas, YSM | 1 |
| Kc, R | 1 |
| Chen, K | 2 |
| Jin, Z | 1 |
| Zhang, M | 1 |
| Lv, L | 1 |
| Gao, Z | 1 |
| Wang, S | 2 |
| Zhou, N | 1 |
| Xia, Y | 1 |
| Cui, J | 2 |
| Jiang, X | 1 |
| Shi, B | 1 |
| Wu, M | 1 |
| Xu, H | 1 |
| Tan, X | 1 |
| Wan, S | 1 |
| Guo, M | 1 |
| Long, Y | 1 |
| Xu, Y | 1 |
| Salama, WM | 1 |
| El-Naggar, SA | 1 |
| Harras, SF | 1 |
| El-Said, KS | 1 |
| Zhang, C | 2 |
| Fix, DK | 1 |
| Montgomery, JA | 1 |
| de Hart, NM | 1 |
| Ferrara, PJ | 1 |
| Kelley, JJ | 1 |
| Eshima, H | 1 |
| Hurley, DJ | 1 |
| Irnaten, M | 1 |
| O'Brien, C | 1 |
| Nesti, L | 1 |
| Natali, A | 1 |
| Yi, H | 1 |
| Huang, C | 1 |
| Shi, Y | 1 |
| Cao, Q | 1 |
| Zhao, Y | 1 |
| Chen, J | 1 |
| Pollock, CA | 1 |
| Chen, XM | 1 |
| Sudhakara, G | 1 |
| Mallaiah, P | 1 |
| Rajendran, R | 1 |
| Saralakumari, D | 1 |
| Asensio-Lopez, MDC | 1 |
| Lax, A | 1 |
| Fernandez Del Palacio, MJ | 1 |
| Sassi, Y | 1 |
| Hajjar, RJ | 1 |
| Pascual-Figal, DA | 1 |
| Liang, D | 1 |
| Liang, W | 1 |
| Liu, S | 1 |
| Kim, JM | 1 |
| Yoo, H | 1 |
| Kim, JY | 1 |
| Oh, SH | 1 |
| Kang, JW | 1 |
| Yoo, BR | 1 |
| Han, SY | 1 |
| Kim, CS | 1 |
| Choi, WH | 1 |
| Lee, EJ | 1 |
| Byeon, HJ | 1 |
| Lee, YS | 1 |
| Cho, J | 1 |
| Dong, G | 1 |
| Ma, M | 1 |
| Lin, X | 1 |
| Liu, H | 1 |
| Gao, D | 1 |
| Ren, Z | 1 |
| Chen, R | 1 |
| Melendez, GC | 1 |
| Lesnefsky, EJ | 1 |
| Abdel-Hamid, AAM | 1 |
| Firgany, AEL | 1 |
| Xu, XX | 1 |
| Zhang, SS | 1 |
| Lin, HL | 1 |
| Lin, Q | 1 |
| Shen, LE | 1 |
| Ansong, E | 1 |
| Appleby, RN | 1 |
| Moghul, I | 1 |
| Khan, S | 1 |
| Yee, M | 1 |
| Manousou, P | 1 |
| Neal, TD | 1 |
| Walters, JRF | 1 |
| Lin, CX | 1 |
| Liang, S | 1 |
| Tao, J | 1 |
| Zhang, LS | 1 |
| Su, YF | 1 |
| Huang, YX | 1 |
| Zhao, ZK | 1 |
| Liu, SY | 1 |
| Zheng, JM | 1 |
| Wang, Y | 2 |
| Zhang, S | 1 |
| Liang, Z | 1 |
| Feng, M | 1 |
| Zhao, X | 1 |
| Qin, K | 1 |
| Gao, C | 1 |
| Li, X | 3 |
| Guo, H | 1 |
| Luo, J | 1 |
| Malekpour-Dehkordi, Z | 1 |
| Teimourian, S | 1 |
| Nourbakhsh, M | 1 |
| Naghiaee, Y | 1 |
| Sharifi, R | 1 |
| Mohiti-Ardakani, J | 1 |
| Ianiro, G | 1 |
| Ponziani, FR | 1 |
| Gasbarrini, A | 1 |
| Cammarota, G | 1 |
| Shen, S | 1 |
| Xia, Yj | 1 |
| Yi, L | 1 |
| Gao, Q | 1 |
| Picatoste, B | 1 |
| Ramírez, E | 1 |
| Caro-Vadillo, A | 1 |
| Iborra, C | 1 |
| Ares-Carrasco, S | 1 |
| Egido, J | 1 |
| Tuñón, J | 1 |
| Lorenzo, O | 1 |
| Edsfeldt, A | 1 |
| Gonçalves, I | 1 |
| Grufman, H | 1 |
| Nitulescu, M | 1 |
| Dunér, P | 1 |
| Bengtsson, E | 1 |
| Mollet, IG | 1 |
| Persson, A | 1 |
| Nilsson, M | 1 |
| Orho-Melander, M | 1 |
| Melander, O | 1 |
| Björkbacka, H | 1 |
| Nilsson, J | 1 |
| Han, Y | 1 |
| Jung, HW | 1 |
| Park, YK | 1 |
| Kim, H | 1 |
| Moon, SY | 1 |
| Kim, JS | 1 |
| Baek, CH | 1 |
| Kim, M | 1 |
| Min, JY | 1 |
| Lee, SK | 1 |
| Rose, TA | 1 |
| Choi, JW | 1 |
| Inthachai, T | 1 |
| Lekawanvijit, S | 1 |
| Kumfu, S | 1 |
| Apaijai, N | 1 |
| Pongkan, W | 1 |
| Chattipakorn, SC | 1 |
| Chattipakorn, N | 1 |
| Cavaglieri, RC | 1 |
| Day, RT | 1 |
| Feliers, D | 1 |
| Abboud, HE | 1 |
| Daskalopoulos, EP | 1 |
| Dufeys, C | 1 |
| Bertrand, L | 1 |
| Beauloye, C | 1 |
| Horman, S | 1 |
| Wang, M | 1 |
| Weng, X | 1 |
| Guo, J | 1 |
| Jiang, G | 1 |
| Li, J | 2 |
| Li, A | 1 |
| Qiu, Z | 1 |
| Qi, LW | 1 |
| Kou, J | 1 |
| Liu, K | 1 |
| Liu, B | 1 |
| Huang, F | 1 |
| Llovet, JM | 1 |
| Zucman-Rossi, J | 1 |
| Pikarsky, E | 1 |
| Sangro, B | 1 |
| Schwartz, M | 1 |
| Sherman, M | 1 |
| Gores, G | 1 |
| Ursini, F | 1 |
| Grembiale, RD | 1 |
| D'Antona, L | 1 |
| Gallo, E | 1 |
| D'Angelo, S | 1 |
| Citraro, R | 1 |
| Visca, P | 1 |
| Olivieri, I | 1 |
| De Sarro, G | 1 |
| Perrotti, N | 1 |
| Russo, E | 1 |
| Mummidi, S | 1 |
| Das, NA | 1 |
| Carpenter, AJ | 1 |
| Kandikattu, H | 1 |
| Krenz, M | 1 |
| Siebenlist, U | 1 |
| Valente, AJ | 1 |
| Chandrasekar, B | 1 |
| Duan, W | 1 |
| Jiang, Z | 1 |
| Chen, X | 1 |
| Sun, L | 1 |
| Lei, J | 1 |
| Xu, Q | 1 |
| Ma, J | 1 |
| Han, L | 1 |
| Wang, Z | 1 |
| Wu, Z | 1 |
| Wu, E | 1 |
| Ma, Q | 1 |
| Ma, Z | 1 |
| Feng, Y | 1 |
| Xiao, H | 2 |
| Sasaki, H | 1 |
| Asanuma, H | 1 |
| Fujita, M | 1 |
| Takahama, H | 1 |
| Wakeno, M | 1 |
| Ito, S | 1 |
| Ogai, A | 1 |
| Asakura, M | 1 |
| Kim, J | 1 |
| Minamino, T | 1 |
| Takashima, S | 1 |
| Sanada, S | 1 |
| Sugimachi, M | 1 |
| Komamura, K | 1 |
| Mochizuki, N | 1 |
| Kitakaze, M | 1 |
| Ma, X | 1 |
| Feng, W | 1 |
| Fu, Y | 1 |
| Xu, M | 1 |
| Shen, Q | 1 |
| Zhu, Y | 1 |
| Cufí, S | 1 |
| Vazquez-Martin, A | 1 |
| Oliveras-Ferraros, C | 1 |
| Martin-Castillo, B | 1 |
| Joven, J | 1 |
| Menendez, JA | 1 |
| González Jiménez, E | 1 |
| Schmidt Río-Valle, J | 1 |
| Álvarez Ferre, J | 1 |
| Yin, M | 1 |
| van der Horst, IC | 1 |
| van Melle, JP | 1 |
| Qian, C | 1 |
| van Gilst, WH | 1 |
| Silljé, HH | 1 |
| de Boer, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806] | Phase 4 | 15 participants (Anticipated) | Interventional | 2022-10-10 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for metformin and Fibrosis
| Article | Year |
|---|---|
Research progress of metformin in the treatment of liver fibrosis.
Topics: Fibrosis; Humans; Hypoglycemic Agents; Liver; Liver Cirrhosis; Metformin | 2023 |
Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms.
Topics: AMP-Activated Protein Kinases; Animals; Enzyme Activation; Enzyme Activators; Extracellular Matrix; | 2021 |
Metformin and Glaucoma-Review of Anti-Fibrotic Processes and Bioenergetics.
Topics: Animals; Fibrosis; Glaucoma; Humans; Metformin; Signal Transduction | 2021 |
Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cardiovascular Diseases; Diabetes Mellitus; Disease | 2017 |
Intravenous Imaging Contrast Media Complications: The Basics That Every Clinician Needs to Know.
Topics: Contrast Media; Extravasation of Diagnostic and Therapeutic Materials; Fibrosis; Gadolinium; Humans; | 2015 |
AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation.
Topics: Aging; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Berberine; Cardiomegaly; Extracell | 2016 |
Hepatocellular carcinoma.
Topics: Aflatoxin B1; Alcohol Drinking; Carcinoma, Hepatocellular; Fibrosis; Hepatitis B; Hepatitis B Vaccin | 2016 |
[Fatty liver and its clinical management in obese adolescents].
Topics: Adiponectin; Adolescent; Apoptosis; Biomarkers; Chemokines; Disease Progression; Fatty Liver; Fibros | 2011 |
1 trial available for metformin and Fibrosis
| Article | Year |
|---|---|
Disuse-induced muscle fibrosis, cellular senescence, and senescence-associated secretory phenotype in older adults are alleviated during re-ambulation with metformin pre-treatment.
Topics: Cellular Senescence; Collagen; Female; Fibrosis; Humans; Inflammation; Male; Metformin; Muscle, Skel | 2023 |
70 other studies available for metformin and Fibrosis
| Article | Year |
|---|---|
Metformin Attenuates Postinfarction Myocardial Fibrosis and Inflammation in Mice.
Topics: Animals; Fibrosis; Hypoglycemic Agents; Inflammation; Male; Metformin; Mice; Mice, Inbred C57BL; Myo | 2021 |
Effect of metformin treatment and its time of administration on joint capsular fibrosis induced by mouse knee immobilization.
Topics: Animals; Contracture; Disease Models, Animal; Fibrosis; Gene Expression; Immobilization; Immunohisto | 2021 |
Letter to the Editor: Comment on Jeon HB, et al. Metformin Inhibits Transforming Growth Factor β-Induced Fibrogenic Response of Human Dermal Fibroblasts and Suppresses Fibrosis in Keloid Spheroids ( Ann Plast Surg . 2021;86:406-411).
Topics: Cells, Cultured; Fibroblasts; Fibrosis; Humans; Keloid; Metformin; Transforming Growth Factor beta; | 2022 |
AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; AMP-Activated Protein Kinases; Animals; Blood Glucose; Blood Urea Nitro | 2021 |
Letter to the Editor: Comment on Jeon HB, et al. Metformin Inhibits Transforming Growth Factor β-Induced Fibrogenic Response of Human Dermal Fibroblasts and Suppresses Fibrosis in Keloid Spheroids ( Ann Plast Surg . 2021;86:406-411).
Topics: Cells, Cultured; Fibroblasts; Fibrosis; Humans; Keloid; Metformin; Transforming Growth Factor beta; | 2022 |
Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis.
Topics: Animals; Drug Therapy, Combination; Female; Fibrosis; Metformin; Mice; Mice, Inbred BALB C; Piperidi | 2022 |
Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans.
Topics: Aged; Anticoagulants; Antiviral Agents; Ascites; Atorvastatin; Carvedilol; Diuretics; Fibrosis; Huma | 2022 |
Co-administration of hydrogen and metformin exerts cardioprotective effects by inhibiting pyroptosis and fibrosis in diabetic cardiomyopathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Fibrosis; Hydrogen; Metformin; | 2022 |
A role for metformin in the treatment of Dupuytren disease?
Topics: Cells, Cultured; Dupuytren Contracture; Fibroblasts; Fibrosis; Humans; Metformin; Neoplasm Recurrenc | 2022 |
[Fucoxanthin regulates Nrf2/Keap1 signaling to alleviate myocardial hypertrophy in diabetic rats].
Topics: Animals; Antioxidants; Atrial Natriuretic Factor; Cardiomegaly; Diabetes Mellitus, Experimental; Fib | 2022 |
Kidney-Targeted Drug Delivery System Based on Metformin-Grafted Chitosan for Renal Fibrosis Therapy.
Topics: Chitosan; Drug Carriers; Drug Delivery Systems; Fibrosis; Humans; Kidney; Low Density Lipoprotein Re | 2022 |
Gentiopicroside alleviates cardiac inflammation and fibrosis in T2DM rats through targeting Smad3 phosphorylation.
Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Diabetes Mellitus, Type 2; Fibrosis; Heart Failure | 2022 |
Metformin prevents age-associated ovarian fibrosis by modulating the immune landscape in female mice.
Topics: Animals; Female; Fibroblasts; Fibrosis; Humans; Metformin; Mice; Myofibroblasts; Ovary | 2022 |
Black pepper oil (Piper nigrum L.) mitigates dexamethasone induced pancreatic damage via modulation of oxidative and nitrosative stress.
Topics: Animals; Blood Glucose; COVID-19 Drug Treatment; Dexamethasone; Dyslipidemias; Fibrosis; Insulin Res | 2022 |
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Biomarkers; Cholesterol; Chol | 2022 |
The combination of exercise and metformin inhibits TGF-β1/Smad pathway to attenuate myocardial fibrosis in db/db mice by reducing NF-κB-mediated inflammatory response.
Topics: Animals; Diabetic Cardiomyopathies; Fibrosis; Interleukin-6; Metformin; Mice; NF-kappa B; Transformi | 2023 |
The combination of exercise and metformin inhibits TGF-β1/Smad pathway to attenuate myocardial fibrosis in db/db mice by reducing NF-κB-mediated inflammatory response.
Topics: Animals; Diabetic Cardiomyopathies; Fibrosis; Interleukin-6; Metformin; Mice; NF-kappa B; Transformi | 2023 |
The combination of exercise and metformin inhibits TGF-β1/Smad pathway to attenuate myocardial fibrosis in db/db mice by reducing NF-κB-mediated inflammatory response.
Topics: Animals; Diabetic Cardiomyopathies; Fibrosis; Interleukin-6; Metformin; Mice; NF-kappa B; Transformi | 2023 |
The combination of exercise and metformin inhibits TGF-β1/Smad pathway to attenuate myocardial fibrosis in db/db mice by reducing NF-κB-mediated inflammatory response.
Topics: Animals; Diabetic Cardiomyopathies; Fibrosis; Interleukin-6; Metformin; Mice; NF-kappa B; Transformi | 2023 |
Deciphering the Antifibrotic Property of Metformin.
Topics: Antigens, CD; Antigens, Neoplasm; Fibrosis; Humans; Lung; Metformin; Phosphatidylinositol 3-Kinases; | 2022 |
Metformin Attenuates Inflammation and Fibrosis in Thyroid-Associated Ophthalmopathy.
Topics: AMP-Activated Protein Kinases; Fibrosis; Graves Ophthalmopathy; Humans; Inflammation; Metformin | 2022 |
Mutation of regulatory phosphorylation sites in PFKFB2 does not affect the anti-fibrotic effect of metformin in the kidney.
Topics: Animals; Disease Models, Animal; Fibrosis; Kidney; Kidney Diseases; Metformin; Mice; Mutation; Phosp | 2023 |
Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension.
Topics: AMP-Activated Protein Kinases; Animals; Down-Regulation; Dyslipidemias; Fibrosis; Hypertension; Infl | 2023 |
Inhaled Lipid Nanoparticles Alleviate Established Pulmonary Fibrosis.
Topics: COVID-19; Fibrosis; Humans; Liposomes; Lung; Metformin; Pulmonary Fibrosis; SARS-CoV-2 | 2023 |
Metformin suppresses cardiac fibroblast proliferation under high-glucose conditions via regulating the mitochondrial complex I protein Grim-19 involved in the Sirt1/Stat3 signaling pathway.
Topics: Animals; Cell Proliferation; Diabetic Cardiomyopathies; Electron Transport Complex I; Fibroblasts; F | 2023 |
Enhanced fatty acid oxidation through metformin and baicalin as therapy for COVID-19 and associated inflammatory states in lung and kidney.
Topics: AMP-Activated Protein Kinases; Animals; COVID-19; Fatty Acids; Fibrosis; Humans; Inflammation; Kidne | 2023 |
Metformin Attenuates TGF-β1-Induced Fibrosis in Salivary Gland: A Preliminary Study.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Fibroblasts; Fibrosis; Humans; Me | 2023 |
Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma.
Topics: Animals; Carbon Tetrachloride; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Disease M | 2019 |
Metformin Abrogates Age-Associated Ovarian Fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Animals; Carcinoma, Ovarian Epithelial; Child, Preschool; Female; Fi | 2020 |
Metformin protects against PM
Topics: AMP-Activated Protein Kinases; Animals; Biomarkers; Biopsy; Cell Line; Disease Models, Animal; Disea | 2020 |
Metformin arrests the progression of established kidney disease in the subtotal nephrectomy model of chronic kidney disease.
Topics: Albuminuria; AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Disease Progression; En | 2020 |
Activation of AMP-Activated Protein Kinases Prevents Atrial Fibrillation.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Atrial | 2021 |
Metformin Inhibits Transforming Growth Factor β-Induced Fibrogenic Response of Human Dermal Fibroblasts and Suppresses Fibrosis in Keloid Spheroids.
Topics: Cells, Cultured; Fibroblasts; Fibrosis; Humans; Keloid; Metformin; Transforming Growth Factor beta; | 2021 |
Metformin decreased myocardial fibrosis and apoptosis in hyperhomocysteinemia -induced cardiac hypertrophy.
Topics: Adult; Animals; Apoptosis; Cardiomegaly; Cells, Cultured; Fibrosis; Heart; Humans; Hyperhomocysteine | 2021 |
Metformin ameliorates ROS-p53-collagen axis of fibrosis and dyslipidemia in type 2 diabetes mellitus-induced left ventricular injury.
Topics: Animals; Collagen; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dyslipidemias; Fibros | 2023 |
Metformin impairs homing ability and efficacy of mesenchymal stem cells for cardiac repair in streptozotocin-induced diabetic cardiomyopathy in rats.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Cell Movement; Cell Survival; Cells, Cultured | 2021 |
Metformin attenuates post-epidural fibrosis by inhibiting the TGF-β1/Smad3 and HMGB1/TLR4 signaling pathways.
Topics: Animals; Failed Back Surgery Syndrome; Fibrosis; HMGB1 Protein; Humans; Male; Metformin; Mice; Mice, | 2021 |
Metformin ameliorates bladder dysfunction in a rat model of partial bladder outlet obstruction.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Cells, Cultured; Cytokines; Diseas | 2021 |
Secukinumab and metformin ameliorate dermal fibrosis by decreasing tissue interleukin-17 levels in bleomycin-induced dermal fibrosis.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bleomycin; Collagen; Disease Models, Animal; Female; Fib | 2021 |
An adjuvant effect of Metformin as an anti-fibrotic agent when administered with the anti-schistosomal Praziquantel in Schistosoma mansoni infected mice.
Topics: Adjuvants, Pharmaceutic; Animals; Anthelmintics; Diabetes Mellitus, Type 2; Fibrosis; Granuloma; Mal | 2021 |
Metformin attenuates renal tubulointerstitial fibrosis via upgrading autophagy in the early stage of diabetic nephropathy.
Topics: Animals; Autophagy; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial | 2021 |
Metformin and leucine increase satellite cells and collagen remodeling during disuse and recovery in aged muscle.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Body Weight; Collagen; Fibrosis; Hindlimb Suspension; | 2021 |
Metformin attenuates folic-acid induced renal fibrosis in mice.
Topics: Albuminuria; Animals; Cell Line; Chemokine CCL2; Collagen Type IV; Disease Models, Animal; Extracell | 2018 |
Caralluma fimbriata and metformin protection of rat pancreas from high fat diet induced oxidative stress.
Topics: Animals; Antioxidants; Apocynaceae; Diet, High-Fat; Fibrosis; Lipid Peroxidation; Male; Metformin; O | 2018 |
Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKCα/Gal-3 pathway reduces left ventricular fibrosis following myocardial infarction.
Topics: Adenylate Kinase; Animals; Cells, Cultured; Culture Media, Conditioned; Enzyme Induction; Fibrosis; | 2018 |
Metformin inhibits TGF-beta 1-induced MCP-1 expression through BAMBI-mediated suppression of MEK/ERK1/2 signalling.
Topics: Animals; Cell Line; Chemokine CCL2; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Fi | 2019 |
Metformin Alleviates Radiation-Induced Skin Fibrosis via the Downregulation of FOXO3.
Topics: Animals; Cells, Cultured; Class Ia Phosphatidylinositol 3-Kinase; Down-Regulation; Fibroblasts; Fibr | 2018 |
Treatment-damaged hepatocellular carcinoma promotes activities of hepatic stellate cells and fibrosis through GDF15.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Fibrosis; Growth Dif | 2018 |
Metformin as a modulator of myocardial fibrosis postmyocardial infarction via regulation of cardiomyocyte-fibroblast crosstalk.
Topics: Fibroblasts; Fibrosis; Humans; Infarction; Metformin; Myocardial Infarction; Myocardium; Myocytes, C | 2018 |
Favorable outcomes of metformin on coronary microvasculature in experimental diabetic cardiomyopathy.
Topics: Animals; Coronary Vessels; Diabetic Cardiomyopathies; Disease Models, Animal; Fibrosis; Hypoglycemic | 2018 |
Metformin Promotes Regeneration of the Injured Endometrium Via Inhibition of Endoplasmic Reticulum Stress-Induced Apoptosis.
Topics: Animals; Apoptosis; Cell Proliferation; Disease Models, Animal; Endometrium; Endoplasmic Reticulum S | 2019 |
Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Bile Acids and Salts; Cholestenones; Diarrhea; | 2019 |
Metformin Attenuates Cyclosporine A-induced Renal Fibrosis in Rats.
Topics: Animals; Creatinine; Cyclosporine; Disease Models, Animal; Fibrosis; Humans; Immunosuppressive Agent | 2019 |
Metformin attenuates bleomycin-induced scleroderma by regulating the balance of Treg/Teff cells and reducing spleen germinal center formation.
Topics: Animals; Bleomycin; Cell Differentiation; Collagen; Disease Models, Animal; Female; Fibrosis; Germin | 2019 |
Metformin reduces fibrosis factors in insulin resistant and hypertrophied adipocyte via integrin/ERK, collagen VI, apoptosis, and necrosis reduction.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Apoptosis; Cell Differentiation; Collagen Type IV; Extracellular | 2019 |
Letter: improvement of clinical outcomes by metformin in metabolic liver disease-a microbiota-dependent mechanism?
Topics: Diabetes Mellitus; Fibrosis; Humans; Liver; Liver Cirrhosis; Metformin; Microbiota; Non-alcoholic Fa | 2019 |
Dehydroepiandrosterone induces ovarian and uterine hyperfibrosis in female rats.
Topics: Animals; Dehydroepiandrosterone; Female; Fibrosis; Hypoglycemic Agents; Hypolipidemic Agents; Metfor | 2013 |
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms.
Topics: Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Diabetes Mellitus, Type 2; Di | 2013 |
Impaired fibrous repair: a possible contributor to atherosclerotic plaque vulnerability in patients with type II diabetes.
Topics: Aged; Antihypertensive Agents; Carotid Artery Diseases; Cytokines; Diabetes Mellitus, Type 2; Diseas | 2014 |
Selective therapeutic effect of cornus officinalis fruits on the damage of different organs in STZ-induced diabetic rats.
Topics: Actins; Animals; Cornus; Diabetes Mellitus, Experimental; Fibrosis; Fruit; Hypoglycemic Agents; Insu | 2014 |
Activation of AMP-activated protein kinase inhibits ER stress and renal fibrosis.
Topics: AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Endoplasmic Reticulum Chaperone BiP; | 2015 |
Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction.
Topics: Adamantane; Angiotensin-Converting Enzyme Inhibitors; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Pe | 2015 |
Metformin prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction.
Topics: Adenylate Kinase; Animals; Anti-Inflammatory Agents; Drug Evaluation, Preclinical; Fibrosis; Kidney | 2015 |
Metformin alleviated EMT and fibrosis after renal ischemia-reperfusion injury in rats.
Topics: Animals; Epithelial-Mesenchymal Transition; Fibrosis; Kidney; Male; Metformin; Random Allocation; Ra | 2016 |
The role of metformin and resveratrol in the prevention of hypoxia-inducible factor 1α accumulation and fibrosis in hypoxic adipose tissue.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Fibrosis; | 2016 |
Oral Metformin Ameliorates Bleomycin-Induced Skin Fibrosis.
Topics: Administration, Oral; Animals; Bleomycin; Disease Models, Animal; Female; Fibrosis; Humans; Metformi | 2016 |
Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone+salt-induced cardiac fibrosis in vivo.
Topics: Adaptor Proteins, Signal Transducing; Aldosterone; AMP-Activated Protein Kinases; Animals; Cardiomeg | 2016 |
Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 2017 |
Metformin attenuates renal fibrosis in both AMPKα2-dependent and independent manners.
Topics: AMP-Activated Protein Kinases; Animals; Fibrosis; Gene Expression Regulation; Kidney; Metformin; Mic | 2017 |
Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apoptosis; Cardiotonic Agents; C | 2009 |
Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway.
Topics: Active Transport, Cell Nucleus; Animals; Aorta, Thoracic; Cardiotonic Agents; Cells, Cultured; Colla | 2010 |
Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.
Topics: Animals; Breast Neoplasms; Cadherins; Cell Line, Tumor; Cellular Senescence; Dogs; Epithelial-Mesenc | 2010 |
Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure.
Topics: AMP-Activated Protein Kinases; Animals; Atrial Natriuretic Factor; Blood Glucose; Cardiotonic Agents | 2011 |